Friday, July 11, 2025

Creating liberating content

Access Denied You don’t have permission to access ” on

As our beloved pets age, their needs change with time,

( Representative AI image) Asian markets were mixed on Friday

Related News

Access Denied You don’t have permission to access ” on this server. Reference #18.adf5d217.1752215691.16ea1cd4 Source link

As our beloved pets age, their needs change with time, and it is essential to adapt to those changes to ensure that they live a long, healthy, and happy life.

(Picture source: Axiom-4) As Indian Air Force Group Captain Shubhanshu Shukla, part of the Axiom-4 (Ax-4) private space mission, prepares to return to Earth on July 14, the crew spent

( Representative AI image) Asian markets were mixed on Friday as investors stayed cautious despite Wall Street hitting record highs.Chinese markets led regional gains, with the Hang Seng Index in

Both Labs and Golden Retrievers are gentle, friendly, and people pleasers– which makes them a great choice for first-time dog owners. But Labs are generally more energetic, excited, and playful

Gallbladder cancer causes a chronic dull ache, or a dragging sensation in the upper right abdominal area, instead of the typical sharp pain from gallstones. The sensation persists as a

Trending News

Access Denied You don’t have permission to access ” on this server. Reference #18.adf5d217.1752215691.16ea1cd4 Source link

Tesla’s entry into India comes at a time when the EV maker is facing reduced sales in Europe and China. (AI image) Elon Musk-led Tesla is set to open its

Market movements are expected to be influenced by India-US trade negotiations and company earnings reports. (AI image) Stock market today: Nifty50 and BSE Sensex, the Indian equity benchmark indices, opened

US President Donald Trump announced a 35 per cent tariff on Canadian imports, effective August 1. The decision was conveyed in a letter to Canadian Prime Minister Mark Carney on

NEW DELHI: The UK has joined Eutelsat’s 1.5 billion euro (nearly $1.8 billion) capital raise, where Bharti Space is committing 150 million euro ($176 million), in a move that arms

Bengaluru: TCS marked its first year-on-year decline in constant currency since the Sept quarter of FY21, with lacklustre performance attributed to weak macroeconomic conditions, cautious client sentiment, delayed decision-making, and

At Rs 58 crore, cancer drug emerges top seller among new launches in 2024

Word Count: 630 | Estimated Reading Time: 4 minutes


At Rs 58 crore, cancer drug emerges top seller among new launches in 2024

NEW DELHI: Enhertu, an oncology drug marketed by UK giant AstraZeneca, topped the list of highest-selling new drugs in 2024, generating sales of nearly Rs 58 crore within its first year of launch. A cancer drug topping the sales charts also highlights the growing incidence of the disease in the country.
In total, over 3,100 new brands were introduced during the year, collectively registering sales of Rs 1,097 crore, the latest data culled from IQVIA showed.
The largest number of new brands were launched in the cardiac, anti-diabetic, and vitamins & minerals categories, reflecting the prevailing disease patterns across the country.
AstraZeneca’s Enhertu (trastuzumab deruxtecan) was followed by Sun Pharma which achieved sales of Rs 50 crore with 18 brands, and Dr Reddy’s Rs 45 crore with 51 brands, the data showed.
Among the brands launched in the last 12 months, gastro reported the highest value of Rs 167 crore from 394 brands, followed by anti-neoplast/immunomodulator (used in cancer therapy) with Rs 150 crore from 94 brands, and vitamins and minerals with a sale of Rs 126 crore from 505 brands.
For context, the top-selling brand in the entire pharmaceutical market, either antibiotic Augmentin or anti-diabetic therapy Mixtard, generates around Rs 75-80 crore in monthly sales.

At Rs 58cr, cancer drug emerges top seller among new launches in 2024.

Overall, the domestic pharma market stands at over Rs 2.2 lakh crore, with growth of a little over 8%.
In Jan, the growth was led by price increases contributing over 5%, and new product introduction 2.6%, while volume growth was 0.9%.
GSK’s Augmentin continued to be number 1 brand with revenues of Rs 830 crore, growing by 9.3% for the 12-month period.
Certain therapies outperformed the pharma retail market, including cardiac at 10.2%, gastro-intestinal at 10.9%, vitamins at 9.2%, neuro at 10% and derma at 10.1%.
As against this, anti-infectives, anti-diabetic, respiratory, pain and gynaecology segments reported sluggish growth.
The market is growing at a steady rate between 8-10% with certain players, including Sun Pharma and Torrent, exhibiting healthy double-digit growth, IQVIA data showed.





Source link

Most Popular Articles

Sign In

Welcome ! Log into Your Account